MIFH
HTGM

Migdal Insurance & Financial Holdings’s HTG Molecular Diagnostics, Inc. Common Stock HTGM Stock Holding History

Migdal Insurance & Financial Holdings’s Portfolio HTGM Stock Details HTGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-110
Closed -$7K – 718
2021
Q4 		$7K Sell
110
-66
-38% -$3.84K ﹤0.01% 635
2021
Q3 		$12K Buy
+176
New +$12.6K ﹤0.01% 587

Other funds holding HTGM

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SC
Samjo Capital New York $254M AUM 36.81% 1-Year Est. Return
CPA
Cowen Prime Advisors New York $290M AUM 57.8% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Migdal Insurance & Financial Holdings's HTGM Position: Q1 2022 in Review

Migdal Insurance & Financial Holdings sold out of HTG Molecular Diagnostics, Inc. Common Stock (HTGM) in Q1 2022, closing a stake of 110 shares — an estimated $7K sold.

Migdal Insurance & Financial Holdings first reported a position in HTGM in Q3 2021 and held it in 2 quarters. The position peaked at $12K in Q3 2021. 21 funds tracked by Wall St. Rank hold HTGM as of Q1 2022.

  • Migdal Insurance & Financial Holdings reported no remaining HTG Molecular Diagnostics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Migdal Insurance & Financial Holdings sold 110 HTG Molecular Diagnostics, Inc. Common Stock shares in Q1 2022, an estimated $7K.
  • Migdal Insurance & Financial Holdings first reported a position in HTG Molecular Diagnostics, Inc. Common Stock in Q3 2021 and held it in 2 quarters.
  • Migdal Insurance & Financial Holdings's HTG Molecular Diagnostics, Inc. Common Stock position peaked at $12K in Q3 2021.
  • 21 funds tracked by Wall St. Rank held HTG Molecular Diagnostics, Inc. Common Stock as of Q1 2022.

Based on Migdal Insurance & Financial Holdings's 13F filing for Q1 2022, filed 2 May 2022.